Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients.

Autor: Villarreal-Garza C; Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, Nuevo Leon, Mexico.; Research and Breast Cancer Department, Instituto Nacional de Cancerologia, Mexico City, Mexico., Lopez-Martinez EA; Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, Nuevo Leon, Mexico., Deneken-Hernandez Z; Fundacion de Cancer de Mama (FUCAM), Mexico City, Mexico., Maffuz-Aziz A; Fundacion de Cancer de Mama (FUCAM), Mexico City, Mexico., Muñoz-Lozano JF; Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, Nuevo Leon, Mexico., Barragan-Carrillo R; Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, Nuevo Leon, Mexico., Ramos-Elias P; Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, Nuevo Leon, Mexico., Moreno B; Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, Nuevo Leon, Mexico., Diaz-Perez H; Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, Nuevo Leon, Mexico., Peña-Curiel O; Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, Nuevo Leon, Mexico., Curiel-Valdez JJ; Grupo Diagnostico Laboratorio Clinico y Patologia, Mexico City, Mexico., Bautista-Piña V; Fundacion de Cancer de Mama (FUCAM), Mexico City, Mexico.

Publikováno v: PloS one [PLoS One] 2020 Mar 11; Vol. 15 (3), pp. e0228884. Date of Electronic Publication: 2020 Mar 11 (Print Publication: 2020).